OncoMatch/Clinical Trials/NCT06450106
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
Is NCT06450106 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies STM-416p for prostate cancer.
Treatment: STM-416p — A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Grade: Grade Group 2Grade Group 3Grade Group 4Grade Group 5 (Grade Group)
Grade Group 2-5
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anticancer therapy
Received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days.
Lab requirements
Blood counts
adequate organ and bone marrow function at screening
Kidney function
adequate organ and bone marrow function at screening
Liver function
adequate organ and bone marrow function at screening
Cardiac function
QTc interval ≤470 msec at Screening
Have adequate organ and bone marrow function at screening. QTc interval >470 msec at Screening [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arizona Urology Specialists · Tucson, Arizona
- University of Florida · Gainesville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06450106 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anticancer therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages